Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003 : Original article  

Evaluation of poly(ADP-ribose) glycohydrolase (PARG) as a therapeutic target for modulation of cellular responses to genotoxic stress

M. Jacobson, R. Meyer, M. Meyer-Ficca, D. Coyle, H. Kim, M. Oliveira, J. Slama, E. Jacobson

Med Sci Monit 2003; 9(1): 29-0 :: ID: 15083

Abstract

Proteins are reversibly modified with ADP-ribose polymers by the combined action of poly(ADP-ribose) polymerases (PARPs) and poly(ADP-ribose) glycohydrolase (PARG). The activation of PARP-1 and PARP-2 following genotoxic stress leads to rapid polymer synthesis, rapid polymer turnover as a result of PARG activity, and it can lead to depletion of cellular NAD. DNA break-activated PARPs are promising targets for the modulation of cellular responses to genotoxic stress and the closely coordinated activities of PARPs and PARG indicates that PARG may also be a good therapeutic target. We have approached target validation of PARG using several approaches. The cloning and expression of the cDNA coding for bovine [1] and human [2] PARG has allowed structural characterizations that make possible molecular genetic approaches to PARG modulation. Photoaffinity labeling and site-directed mutagenesis has led to the identification of three acidic residues essential for catalytic activity, allowing the expression of dominant negative forms of PARG. The cDNA sequence has allowed the design of RNA interference approaches for modulating PARG activity. The discovery of a sensitive and selective inhibitor of PARG [3], ADP-HPD, has led to the synthesis of a cell permeable inhibitor that can be used to modulate PARG activity in cultured cells. This presentation will compare the efficiency of the different approaches in modulating PARG activity and the effects of PARG modulation on NAD and ADP-ribose polymer metabolism and biological responses to genotoxic stress. Supported by grants from the NIH (CA-43894) and Niadyne, Inc. RGM was supported by NIH Cancer Biology Training Grant CA-09213.References: 1.Lin et al: J Biol Chem, 1997; 272: 11895-11901 2.Meyer et al: 2003, submitted 3.Slama et al: J Med Chem, 1995; 38: 389-393

Keywords: Poly(ADP-ribose) glycohydrolase, PARG, therapeutic targets, genotoxic stress

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750